Aug 27 (Reuters) - Amylyx Pharmaceuticals (AMLX.O) said on Wednesday it will stop development of its experimental drug for a rare brain disorder after it failed to improve symptoms in patients during a mid-stage trial.

Shares of the company fell 1.7% in premarket trading after the drug, AMX0035, showed no benefit over a placebo at 24 weeks in patients with a rare and fatal brain disorder called progressive supranuclear palsy (PSP). 

Read the article.